Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Description of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

Introduction to Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811)

The human body is a complex system that relies on a variety of cellular interactions for proper functioning. One important aspect of this communication is the interaction between chemokine receptors and their ligands. The chemokine receptor CD198, also known as CCR8, is a member of the G-protein coupled receptor family and plays a crucial role in immune response and inflammation. Dysregulation of CD198 has been linked to various diseases, making it a potential therapeutic target. In this article, we will discuss the structure, activity, and application of Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811), a novel antibody designed to target CD198.

Structure of CD198

CD198 is a seven-transmembrane protein that belongs to the G-protein coupled receptor family. It is predominantly expressed on immune cells, such as T cells, B cells, and monocytes, and is involved in their migration and activation. The extracellular domain of CD198 contains four cysteine residues that form disulfide bonds, which are essential for its structure and function. The intracellular domain of CD198 interacts with G-proteins, leading to downstream signaling.

Activity of CD198

CD198 is activated by its ligands, CCL1 and CCL18, which are chemokines secreted by various cell types, including immune cells and fibroblasts. Upon binding to its ligands, CD198 undergoes conformational changes that activate G-proteins and initiate downstream signaling pathways. These pathways are involved in cell migration, proliferation, and survival, making CD198 a critical player in immune response and inflammation.

Application of Research Grade Anti-Human CD198/CCR8

The dysregulation of CD198 has been linked to various diseases, including asthma, allergies, and autoimmune disorders. Therefore, targeting CD198 with specific antibodies has emerged as a potential therapeutic strategy. Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) is a novel antibody designed to specifically bind to CD198 and block its activity. This antibody has been extensively studied in preclinical models and has shown promising results in inhibiting immune cell migration and reducing inflammation.

Therapeutic Potential of Research Grade Anti-Human CD198/CCR8

The therapeutic potential of Research Grade Anti-Human CD198/CCR8 lies in its ability to modulate immune response and inflammation. By blocking the activity of CD198, this antibody can prevent the recruitment of immune cells to the site of inflammation, thereby reducing tissue damage. This makes it a potential treatment option for diseases such as asthma, allergies, and autoimmune disorders, where excessive inflammation plays a significant role in disease progression.

Advantages of Research Grade Anti-Human CD198/CCR8

Research Grade Anti-Human CD198/CCR8 has several advantages over other therapeutic options. Firstly, it is a highly specific antibody that only targets CD198, leaving other chemokine receptors unaffected. This reduces the risk of off-target effects and improves the safety profile of the antibody. Secondly, this antibody has a long half-life, allowing for less frequent dosing, which can improve patient compliance. Additionally, Research Grade Anti-Human CD198/CCR8 is produced using advanced recombinant technology, ensuring high purity and consistency in its activity.

Conclusion

In conclusion, Research Grade Anti-Human CD198/CCR8 (GS-1811/JTX-1811) is a novel antibody with the potential to target CD198 and modulate immune response and inflammation. Its specific binding to CD198 and long half-life make it a promising therapeutic option for various diseases. Further clinical studies are needed to fully evaluate the efficacy and safety of this antibody in human patients. However, the current preclinical data supports the potential of Research Grade Anti-Human CD198/CCR8 as a therapeutic target for diseases characterized by dysregulated CD198 activity.